Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
3650- SIL,    Silibinin: a novel inhibitor of Aβ aggregation
- in-vitro, AD, SH-SY5Y
*Aβ↓, *H2O2↓,
3649- SIL,    Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis
*Inflam↓, *NF-kB↓, *cJun↓, *Casp↓, *ROS↓, *lipid-P↓,
3648- SIL,    Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
- Review, NA, NA
*antiOx↑, *Inflam↓, *lipid-P↓, *necrosis↓, *hepatoP↑, *IL1↓, *IL6↓, *TNF-α↓, *IFN-γ↓, MAPK↓, Apoptosis↑, Cyt‑c↑, Casp3↑, Casp9↑, *PPARγ↑, *GLUT4↑, *HSPs↓, *HSP27↑, *Trx↑, *SIRT1↑, *ALAT↓, *GSH↑, *lipid-P↓, *TNF-α↓, TumCG↓, P21↑, CDK4↑,
3646- SIL,    "Silymarin", a promising pharmacological agent for treatment of diseases
- Review, NA, NA
*P-gp/ABCB1↓, *Inflam↓, *hepatoP↑, *antiOx↑, *GSH↑, *BioAv↑, *SOD↑, *IFN-γ↓, *IL4↓, *IL10↓, *Half-Life↓, *TNF-α↓, *ALAT↓, *AST↓, Akt↓, chemoP↑, β-catenin/ZEB1↓, TumCP↓, MMP↓, Cyt‑c↑, *RenoP↑, *BBB↑,
3326- SIL,    Silymarin suppresses proliferation of human hepatocellular carcinoma cells under hypoxia through downregulation of the HIF-1α/VEGF pathway
- in-vitro, Liver, HepG2 - in-vitro, Liver, Hep3B
*hepatoP↑, chemoPv↑, ChemoSen↑, TumCP↓, TumCMig↓, TumCI↓, Hif1a↓, VEGF↓, angioG↓,
3313- SIL,    Silymarin attenuates post-weaning bisphenol A-induced renal injury by suppressing ferroptosis and amyloidosis through Kim-1/Nrf2/HO-1 signaling modulation in male Wistar rats
- in-vivo, NA, NA
*NRF2↑, *HO-1↑, *creat↓, *BUN↓, *RenoP↑, *MDA↓, *TNF-α↓, *IL1β↓, *Cyt‑c↓, *Casp3↓, *GSTs↓, *GSH↑, *GPx4↑, *SOD↑, *GSR↓, *Ferroptosis↓,
3333- SIL,    Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice
- in-vivo, NA, NA
*GRP78/BiP↓, *XBP-1↓,
3332- SIL,    Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2
- in-vitro, Lung, A549
*antiOx↑, *hepatoP↑, MMP2↓, uPA↓, TIMP2↑,
3331- SIL,    The clinical anti-inflammatory effects and underlying mechanisms of silymarin
- Review, NA, NA
*Inflam↓, *NF-kB↓, *NLRP3↓, *COX2/PTGS2↓, *iNOS↓, *neuroP↑, *p‑ERK↓, *p38↓, *MAPK↓, *EGFR↓, *ROS↓, *lipid-P?, *5LO↓,
3330- SIL,    Mechanistic Insights into the Pharmacological Significance of Silymarin
- Review, Var, NA
*neuroP↑, *hepatoP↑, *cardioP↑, *antiOx↓, *NLRP3↓, *NAD↑, ROS↓, NLRP3↓, TumCMig↓, *COX2/PTGS2↓, *iNOS↓, *MPO↓, *AChE↓, *LDH↓, *Telomerase↓, *Fas↓,
3329- SIL,    Silymarin regulates the HIF-1 and iNOS expression in the brain and Gills of the hypoxic-reoxygenated rainbow trout (Oncorhynchus mykis)
- in-vivo, Nor, NA
*NO↓, *MDA↓, *TAC↑, *Hif1a↓, *iNOS↓,
3328- SIL,    Modulatory effect of silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia: emphasis on PTEN, HIF-1α, and NF-κB
- in-vivo, BPH, NA
*NF-kB↓, *Hif1a↓, *PTEN↑, *Weight↓, *NO↓, *IL6↓, *IL8↓, *COX2/PTGS2↓, *iNOS↓,
3327- SIL,    Effects of silymarin on HIF‑1α and MDR1 expression in HepG‑2 cells under hypoxia
- in-vitro, Liver, HepG2
MDR1↓, Hif1a↓, P-gp/ABCB1↓,
3325- SIL,    Modulatory effect of silymarin on pulmonary vascular dysfunction through HIF-1α-iNOS following rat lung ischemia-reperfusion injury
- in-vivo, Nor, NA
*Inflam↓, *ROS↓, *Casp3↑, *Casp9↑, *Hif1a↓, *iNOS↓, *SOD↑, *MDA↓,
3324- SIL,    Silymarin prevents NLRP3 inflammasome activation and protects against intracerebral hemorrhage
*ROS↓, *TAC↑, *NF-kB↓, *IL2↓, *NRF2↑, *HO-1↑, *neuroP↑, *Inflam↓, *NLRP3↓,
3323- SIL,    Anticancer therapeutic potential of silibinin: current trends, scope and relevance
- Review, Var, NA
Inflam↓, angioG↓, antiOx↑, TumMeta↓, TumCP↓, TumCCA↑, TumCD↑, α-SMA↓, p‑Akt↓, p‑STAT3↓, COX2/PTGS2↓, IL6↓, MMP2↓, HIF-1↓, Snail↓, Slug↓, Zeb1↓, NF-kB↓, p‑EGFR↓, JAK2↓, PI3K↓, PD-L1↓, VEGF↓, CDK4↓, CDK2↓, cycD1/CCND1↓, E2Fs↓,
3322- SIL,    Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression
- in-vitro, Lung, A549 - in-vitro, Lung, H1299 - in-vitro, Lung, H460
HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, HDAC8↓, HATs↑, Zeb1↓, E-cadherin↑, TumCMig↓,
3321- SIL,    Silymarin (Milk thistle)
- Review, AD, NA
*neuroP↝, *Dose↝, *Half-Life?, *BioAv↝, *cognitive↑, *Aβ↓, *Inflam↓, *OS↑, *memory↑,
3320- SIL,    Neuroprotective Potential of Silymarin against CNS Disorders: Insight into the Pathways and Molecular Mechanisms of Action
- Review, AD, NA
*hepatoP↑, *neuroP↑, *ROS↓, *β-Amyloid↓, *Inflam↓, *Aβ↓, *NF-kB↓, *TNF-α↓, *LTA/TNF-β↓, *iNOS↓, *NO↓, *COX2/PTGS2↓,
3319- SIL,    Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms
- Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*neuroP↑, *ROS↓, *Inflam↓, *Apoptosis↓, *BBB?, *tau↓, *NF-kB↓, *IL1β↓, *TNF-α↓, *IL4↓, *MAPK↓, *memory↑, *cognitive↑, *Aβ↓, *ROS↓, *lipid-P↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *AChE↓, *BChE↓, *p‑ERK↓, *p‑JNK↓, *p‑p38↓, *GutMicro↑, *COX2/PTGS2↓, *iNOS↓, *TLR4↓, *neuroP↑, *Strength↑, *AMPK↑, *MMP↑, *necrosis↓, *NRF2↑, *HO-1↑,
3318- SIL,    Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight
- Review, AD, NA - Review, Park, NA
*hepatoP↑, *neuroP↑, *TLR4↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *memory↑, *cognitive↑, *NRF2↑, *HO-1↑, *ROS↓, *Akt↑, *mTOR↑, *SOD↑, *Catalase↑, *GSH↑, *IL10↑, *IL6↑, *NO↓, *MDA↓, *AChE↓, *MAPK↓, *BDNF↑,
3317- SIL,    Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer's Disease and Other Neurological Disorders
- Review, NA, NA
*neuroP↑,
3316- SIL,  Chemo,    Silymarin Nanoparticles Counteract Cognitive Impairment Induced by Doxorubicin and Cyclophosphamide in Rats; Insights into Mitochondrial Dysfunction and Nrf2/HO-1 Axis
Inflam↓, antiOx↓, neuroP↑, cognitive↑, NRF2↑, HO-1↑, memory↑, AChE↓, Casp3↓,
3315- SIL,    Silymarin alleviates docetaxel-induced central and peripheral neurotoxicity by reducing oxidative stress, inflammation and apoptosis in rats
- in-vivo, Nor, NA
neuroP↑, *NRF2↑, *HO-1↑, *lipid-P↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *NF-kB↓, *TNF-α↓, *JNK↓, *Bcl-2↑, *BAX↑,
3314- SIL,    Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative review
- Review, NA, NA
*antiOx↑, *hepatoP↑, *Half-Life↑, *ROS↓, *GSH↑, *hepatoP↑, *lipid-P↓, *TNF-α↓, *IFN-γ↓, *IL2↓, *IL4↓, *NF-kB↓, *iNOS↓, *OATPs↓, *OCT4↓, *Inflam↓, *PGE2↓, MMPs↓, VEGF↓, angioG↓, STAT3↓, *ALAT↓, *AST↓, Dose↝,
1316- SIL,  Chemo,    Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity
- Analysis, Var, NA
TumCCA↑, p42↓, P450↓, OATPs↓, chemoP↑, ChemoSen↑,
1276- SIL,    Silibinin inhibits TPA-induced cell migration and MMP-9 expression in thyroid and breast cancer cells
- in-vitro, BC, NA - in-vitro, Thyroid, NA
TumCMig↓, MMP9↓, p‑MEK↓, p‑ERK↓,
109- SIL,    Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma
- vitro+vivo, RCC, 769-P - in-vitro, RCC, 786-O - in-vitro, RCC, ACHN - in-vitro, RCC, OS-RC-2
HH↓, Gli1↓, GLI2↓, mTOR↓, Bcl-2↓, Apoptosis↑, Casp3↑, PARP↑, TumCG↓,
1140- SIL,    Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth
- in-vitro, PC, AsPC-1 - in-vivo, PC, NA - in-vitro, PC, MIA PaCa-2 - in-vitro, PC, PANC1 - in-vitro, PC, Bxpc-3
TumCG↓, Glycolysis↓, cMyc↓, STAT3↓, TumCP↓, Weight∅, Strength↑, DNAdam↑, Casp3↑, Casp9↑, GLUT1↓, HK2↓, LDHA↓, GlucoseCon↓, lactateProd↓, PPP↓, Ki-67↓, p‑STAT3↓, cachexia↓,
1127- SIL,    Silibinin suppresses epithelial–mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1
- in-vitro, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, EMT↓, RHBDD1↓,
964- SIL,    Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics
- vitro+vivo, Pca, LNCaP - in-vitro, Pca, 22Rv1
TumCP↓, Hif1a↓, NADPH↓, angioG↓, FASN↓, ACC↓,
1001- SIL,    Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism
- in-vitro, NA, NA
TumCG↓, Glycolysis↓, OXPHOS↑, LDHA↓, lactateProd↓, i-citrate↑, Hif1a↓, PD-L1↓,
978- SIL,    A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment
- Review, NA, NA
PI3K↓, Akt↓, NF-kB↓, Wnt/(β-catenin)↓, MAPK↓, TumCP↓, TumCCA↑, Apoptosis↑, p‑EGFR↓, JAK2↓, STAT5↓, cycD1/CCND1↓, hTERT/TERT↓, AP-1↓, MMP9↓, miR-21↓, miR-155↓, Casp9↑, BID↑, ERK↓, Akt2↓, DNMT1↓, P53↑, survivin↓, Casp3↑, ROS↑,
4206- SIL,    Silymarin ameliorates experimentally induced depressive like behavior in rats: Involvement of hippocampal BDNF signaling, inflammatory cytokines and oxidative stress response
- in-vivo, NA, NA
*BDNF↑, *5HT↑, *antiOx↑, *IL6↓, *TNF-α↓, *Mood↑,
4205- SIL,    The Therapeutic Effect of Silymarin and Silibinin on Depression and Anxiety Disorders and Possible Mechanism in the Brain: A Systematic Review
- Review, AD, NA
*BDNF↑, *5HT↑, *MDA↓, *GSH↑, *SOD↑, *Catalase↑, *IL6↓, *IL1β↓,
4207- SIL,    Silymarin sex-dependently improves cognitive functions and alters TNF-α, BDNF, and glutamate in the hippocampus of mice with mild traumatic brain injury
*TNF-α↓, *BDNF↑, *cognitive↑,
2306- SIL,  CUR,  RES,  EA,    Identification of Natural Compounds as Inhibitors of Pyruvate Kinase M2 for Cancer Treatment
- in-vitro, BC, MDA-MB-231
PKM2↓, Dose↝, Dose↝,
2410- SIL,    Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF
- in-vitro, GBM, U87MG - in-vitro, GBM, U251 - in-vivo, NA, NA
TumAuto↑, ATP↓, Glycolysis↓, H2O2↑, P53↑, GSH↓, xCT/SLC7A11↓, BNIP3↝, MMP↑, mt-ROS↑, mtDam↑, HK2↓, PFKP↓, PKM2↓, TumCG↓,
4122- Silicon,    Silicon-rich mineral water as a non-invasive test of the 'aluminum hypothesis' in Alzheimer's disease
- Trial, AD, NA
*other↓, *other∅, *cognitive↑,
4123- Silicon,    The potential influence of silica present in drinking water on Alzheimer's disease and associated disorders
- Review, AD, NA
*Aβ↓, *cognitive↝,
4136- Silicon,    Aluminum Should Now Be Considered a Primary Etiological Factor in Alzheimer’s Disease
- Review, AD, NA
*cognitive↑, *Risk↓, *neuroP↑,
4134- Silicon,    Garden Cress (Lepidium sativum) Seeds Ameliorated Aluminum-Induced Alzheimer Disease in Rats Through Antioxidant, Anti-Inflammatory, and Antiapoptotic Effects
- in-vivo, AD, NA
*neuroP↑, *BioAv↓, *cognitive↑,
4133- Silicon,    Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study
- Study, AD, NA
*Risk↓, *Dose↑, *neuroP↑,
4131- Silicon,    Silicon reduces aluminum accumulation in rats: relevance to the aluminum hypothesis of Alzheimer disease
- Study, Nor, NA
*other↓, *BioAv↓, *neuroP↑,
4129- Silicon,    Silica and aluminum in drinking water and cognitive impairment in the elderly
- Study, AD, NA
*cognitive↑,
4125- Silicon,    Oral silicon supplementation: an effective therapy for preventing oral aluminum absorption and retention in mammals
- Review, AD, NA
*neuroP↑, *BioAv↓,
4126- Silicon,  H2,    Oral Administration of Si-Based Agent Attenuates Oxidative Stress and Ischemia-Reperfusion Injury in a Rat Model: A Novel Hydrogen Administration Method
- in-vivo, NA, NA
*creat↓, *ROS↓, *other↑, *MDA↓, *other↑, *Inflam↓,
4128- Silicon,    Silicon as Versatile Player in Plant and Human Biology: Overlooked and Poorly Understood
- Review, NA, NA
*other↑, *BMD↑, *Dose↝, *cognitive↑, *Dose?,
4127- Silicon,    Interference of Parenteral Nutrition Components in Silicon-Mediated Protection Against Aluminum Bioaccumulation
- in-vivo, AD, NA
*other↓, *neuroP↑,
2359- SK,    Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
- in-vivo, Liver, NA
TumCG↓, PKM2↓, EMT↓, TGF-β↓, Glycolysis↓, lactateProd↓, ATP↓,

Showing Research Papers: 7451 to 7500 of 8276
Prev Page 150 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8276

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 1,   GSH↓, 1,   H2O2↑, 1,   HO-1↑, 1,   NRF2↑, 1,   OXPHOS↑, 1,   ROS↓, 1,   ROS↑, 1,   mt-ROS↑, 1,   xCT/SLC7A11↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 2,   p‑MEK↓, 1,   MMP↓, 1,   MMP↑, 1,   mtDam↑, 1,   p42↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↓, 1,   i-citrate↑, 1,   cMyc↓, 1,   FASN↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 4,   HK2↓, 2,   lactateProd↓, 3,   LDHA↓, 2,   NADPH↓, 1,   PFKP↓, 1,   PKM2↓, 3,   PPP↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   p‑Akt↓, 1,   Apoptosis↑, 3,   Bcl-2↓, 1,   BID↑, 1,   Casp3↓, 1,   Casp3↑, 4,   Casp9↑, 3,   Cyt‑c↑, 2,   hTERT/TERT↓, 1,   MAPK↓, 2,   survivin↓, 1,   TumCD↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

HATs↑, 1,   miR-21↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

BNIP3↝, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   DNMT1↓, 1,   P53↑, 2,   PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   CDK4↑, 1,   cycD1/CCND1↓, 2,   E2Fs↓, 1,   P21↑, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 2,   ERK↓, 1,   p‑ERK↓, 1,   Gli1↓, 1,   HDAC↓, 1,   HDAC1↓, 1,   HDAC2↓, 1,   HDAC3↓, 1,   HDAC8↓, 1,   HH↓, 1,   mTOR↓, 1,   PI3K↓, 2,   STAT3↓, 2,   p‑STAT3↓, 2,   STAT5↓, 1,   TumCG↓, 6,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

Akt2↓, 1,   AP-1↓, 1,   E-cadherin↑, 1,   GLI2↓, 1,   Ki-67↓, 1,   miR-155↓, 1,   MMP2↓, 2,   MMP9↓, 2,   MMPs↓, 1,   RHBDD1↓, 1,   Slug↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TIMP2↑, 1,   TumCI↓, 2,   TumCMig↓, 5,   TumCP↓, 7,   TumMeta↓, 1,   uPA↓, 1,   Zeb1↓, 2,   α-SMA↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 4,   p‑EGFR↓, 2,   HIF-1↓, 1,   Hif1a↓, 4,   VEGF↓, 3,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,   OATPs↓, 1,   P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL6↓, 1,   Inflam↓, 2,   JAK2↓, 2,   NF-kB↓, 2,   PD-L1↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 2,   Dose↝, 3,   MDR1↓, 1,   P450↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

p‑EGFR↓, 2,   hTERT/TERT↓, 1,   IL6↓, 1,   Ki-67↓, 1,   PD-L1↓, 2,  

Functional Outcomes(tgid=23) ⓘ

cachexia↓, 1,   chemoP↑, 2,   chemoPv↑, 1,   cognitive↑, 1,   memory↑, 1,   neuroP↑, 2,   Strength↑, 1,   Weight∅, 1,  
Total Targets: 130

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 5,   Catalase↑, 4,   Ferroptosis↓, 1,   GPx↑, 1,   GPx4↑, 1,   GSH↑, 8,   GSR↓, 1,   GSTs↓, 1,   H2O2↓, 1,   HO-1↑, 5,   lipid-P?, 1,   lipid-P↓, 6,   MDA↓, 7,   MPO↓, 1,   NRF2↑, 5,   ROS↓, 10,   SOD↑, 7,   TAC↑, 2,   Trx↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 3,   AMPK↑, 1,   BUN↓, 1,   LDH↓, 1,   NAD↑, 1,   PPARγ↑, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↑, 1,   Apoptosis↓, 1,   BAX↑, 1,   Bcl-2↑, 1,   Casp↓, 1,   Casp3↓, 1,   Casp3↑, 1,   Casp9↑, 1,   Cyt‑c↓, 1,   Fas↓, 1,   Ferroptosis↓, 1,   iNOS↓, 8,   JNK↓, 1,   p‑JNK↓, 1,   MAPK↓, 3,   necrosis↓, 2,   p38↓, 1,   p‑p38↓, 1,   Telomerase↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 1,   other↓, 3,   other↑, 3,   other∅, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

GRP78/BiP↓, 1,   HSP27↑, 1,   HSPs↓, 1,   XBP-1↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑ERK↓, 2,   mTOR↑, 1,   OCT4↓, 1,   PTEN↑, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 1,   Hif1a↓, 3,   NO↓, 4,  

Barriers & Transport(tgid=15) ⓘ

BBB?, 1,   BBB↑, 1,   GLUT4↑, 1,   OATPs↓, 1,   P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 5,   IFN-γ↓, 3,   IL1↓, 1,   IL10↓, 1,   IL10↑, 1,   IL1β↓, 4,   IL2↓, 2,   IL4↓, 3,   IL6↓, 4,   IL6↑, 1,   IL8↓, 1,   Inflam↓, 11,   LTA/TNF-β↓, 1,   NF-kB↓, 9,   PGE2↓, 1,   TLR4↓, 2,   TNF-α↓, 11,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 2,   AChE↓, 3,   BChE↓, 1,   BDNF↑, 4,   tau↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 5,   NLRP3↓, 3,   β-Amyloid↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 1,   BioAv↝, 1,   Dose?, 1,   Dose↑, 1,   Dose↝, 2,   Half-Life?, 1,   Half-Life↓, 1,   Half-Life↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 3,   AST↓, 2,   BMD↑, 1,   creat↓, 2,   EGFR↓, 1,   GutMicro↑, 1,   IL6↓, 4,   IL6↑, 1,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   cognitive↑, 9,   cognitive↝, 1,   hepatoP↑, 9,   memory↑, 3,   Mood↑, 1,   neuroP↑, 14,   neuroP↝, 1,   OS↑, 1,   RenoP↑, 2,   Risk↓, 2,   Strength↑, 1,   Weight↓, 1,  
Total Targets: 124

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page